GANX · Gain Therapeutics Inc
United States · RS rating 13 · As of 2026-11-03
| Price | 1.15 USD |
|---|---|
| 1-day change | +1.8% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 11 / 16 / 25 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 6 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +15.4% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +72.5% |
| Market cap (USD) | $80.3M |